论文部分内容阅读
目的 观察重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床疗效及安全性.方法 将60例恶性胸腔积液患者随机分为对照组和试验组,每组30例.对照组予以顺铂每次60 mg,每周2次,胸腔灌注;试验组在对照组治疗的基础上,予以重组人血管内皮抑制素每次45 mg,每周2次,胸腔灌注.2组患者均治疗3个月,每月顺铂剂量不超过120 mg,胸水消失停止治疗.比较2组患者的临床疗效和药物不良反应的发生情况.结果 治疗后,试验组和对照组的疾病控制率分别为80.00％(24例/30例)和60.00％(1 8例/30例),差异有统计学意义(P＜0.05).2组患者的药物不良反应以胃肠道反应、发热、乏力、白细胞减少、血小板减少和肝肾功能损害为主,且其发生率比较,差异均无统计学意义(均P ＞0.05).结论 重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床疗效确切,且不增加药物不良反应发生率.“,”Objective To observe the clinical efficacy and safety of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion.Methods Sixty patients with malignant pleural effusion were randomly divided into control and treatment group with 30 cases per group.Control group was given 60 mg per time,twice a week,thoracic perfusion.Treatment group was given recombinant human endostatin 45 mg per time,twice a week,thoracic perfusion,on the basis of control group.Two groups were treated for 3 months.The dose of cisplatin is not more than 120 mg per month,and the disappearance of hydrothorax is stopped.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the disease control rates of treatment and control groups were 80.00％ (24 cases / 30 cases) and 60.00％ (18 cases / 30 cases) with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were gastrointestinal reactions,fever,fatigue,leukopenia,thrombocytopenia,liver and kidney function damage,and their incidences of adverse drug reactions had no statistically significant difference (all P ＞0.05).Conclusion Recombinant human endostatin injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of malignant pleural effusion,without increasing the incidence of adverse drug reactions.